GlassScriptPhysician profile
Mary E Cole
NPI 1205861440
$6,545.80
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,598 · 2022: $2,536 · 2023: $2,412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,347 · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,347.28 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,298.57 | 2021-2023 | |
| Mallinckrodt Hospital Products INC. | $911.25 | 2021-2023 | Acthar |
| Amgen INC. | $639.50 | 2021-2023 | Enbrel, Otezla, Tavneos |
| Ucb, INC. | $588.54 | 2021-2023 | Cimzia |
| Janssen Biotech, INC. | $509.58 | 2021-2023 | Tremfya, Simponi, Stelara |
| Novartis Pharmaceuticals Corporation | $434.70 | 2021-2023 | |
| Glaxosmithkline, LLC. | $397.43 | 2021-2023 | Benlysta |
| Pfizer INC. | $322.65 | 2021-2023 | |
| Lilly USA, LLC | $268.96 | 2021-2023 | Taltz |
| Aurinia Pharma U.S., INC. | $248.61 | 2021-2023 | Lupkynis |
| Radius Health, INC. | $161.06 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $154.63 | 2021-2023 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $147.21 | 2022-2023 | Orencia |
| Horizon Therapeutics Plc | $112.64 | 2021-2023 | Krystexxa |
| Ani Pharmaceuticals, INC. | $104.64 | 2022-2023 | Purified Cortrophin Gel |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.30 | 2021-2023 | Ofev |
| Genzyme Corporation | $46.40 | 2023 | |
| Genentech USA, INC. | $44.75 | 2021-2023 | Actemra |
| Sandoz INC. | $36.12 | 2023 | Hyrimoz |
| Bioventus LLC | $25.57 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $13.50 | 2021 | |
| Boston Scientific Corporation | $13.19 | 2023 | Infinion 16 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Cole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.